 |
DOI: 10.1176/appi.books.9780890423905.154688
Practice Guideline for the Treatment of Patients With Panic Disorder, Second Edition
Work
Group on Panic Disorder
Murray B. Stein, M.D., M.P.H., Chair
Marcia K. Goin, M.D., Ph.D.
Mark H. Pollack, M.D.
Peter Roy-Byrne, M.D.
Jitender Sareen, M.D.
Naomi M. Simon, M.D., M.Sc.
Laura Campbell-Sills, Ph.D., consultant
This practice guideline was approved in July
2008 and published in January 2009.
A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available.
For the period from September 2005 to June 2008, Dr. Stein
reports receiving research grants from the National Institute of Mental
Health, the Department of Veterans Affairs, the Department of Defense,
Eli Lilly and Company, Forest Pharmaceuticals, Inc., Hoffmann-La
Roche, Inc., Novartis, Pfizer, GlaxoSmithKline, Solvay, UCB, and
Wyeth. He reports receiving consultant fees from Allergan, Inc.,
ALZA Corporation, Alexza Molecular Delivery Corp., AstraZeneca,
Avera Pharmaceuticals, BrainCells Inc., Bristol-Myers Squibb, Cephalon,
Comprehensive NeuroScience, Eli Lilly and Company, EPI-Q Inc., Forest Pharmaceuticals,
Inc., GlaxoSmithKline, Hoffmann-La Roche, Inc., Integral Health
Decisions Inc., Janssen Research Foundation, Jazz Pharmaceuticals,
Inc., Johnson & Johnson, Mindsite, Pfizer, sanofi-aventis, Solvay,
Transcept Pharmaceuticals, Inc., UCB, and Wyeth. He reports receiving
honoraria from Eli Lilly and Company, GlaxoSmithKline, Solvay, and
Wyeth.
For the period from October 2005 to June 2008, Dr. Goin reports
no competing interests.
For the period from September 2005 to June 2008, Dr. Pollack
reports serving on advisory boards and doing consultation for AstraZeneca,
BrainCells Inc., Bristol-Myers Squibb, Cephalon, Dov Pharmaceutical
Inc., Forest Pharmaceuticals, Inc., GlaxoSmithKline, Janssen, Jazz
Pharmaceuticals, Inc., Eli Lilly and Company, MedAvante, Neurocrine
Biosciences, Neurogen Corp., Novartis, Otsuka Pharmaceutical, Pfizer,
Predix Pharmaceuticals, Roche, sanofi-aventis, Sepracor Inc., Solvay,
Tikvah Therapeutics, Inc., Transcept Pharmaceuticals, Inc., UCB,
and Wyeth. He reports receiving research grants from AstraZeneca, Bristol-Myers
Squibb, Cephalon, Cyberonics, Forest Pharmaceuticals, Inc., GlaxoSmithKline,
Janssen, Eli Lilly and Company, National Alliance for Research on
Schizophrenia and Depression, the National Institute on Drug Abuse,
the National Institute of Mental Health, Pfizer, Roche, Sepracor
Inc., UCB, and Wyeth. He reports receiving speaker fees from Bristol-Myers
Squibb, Forest Pharmaceuticals, Inc., GlaxoSmithKline, Janssen,
Eli Lilly and Company, Pfizer, Solvay, and Wyeth. He reports equity holdings
in MedAvante and Mensante Corporation. He reports receiving copyright
royalties for the Structured Interview Guide to the Hamilton-A (SIGH-A)
and SAFER.
For the period from August 2004 to June 2008, Dr. Roy-Byrne
reports receiving consultant or advisory fees from Jazz Pharmaceuticals,
Inc., and Solvay. He reports receiving speaker honoraria (via a
continuing medical education company) from Forest Pharmaceuticals,
Inc., Pfizer, and Wyeth.
For the period from August 2005 to June 2008, Dr. Sareen reports
receiving honoraria from Wyeth, AstraZeneca, Lundbeck, and GlaxoSmithKline.
For the period from September 2005 to June 2008, Dr. Simon
reports receiving research support from Cephalon, Pfizer, AstraZeneca,
Forest Pharmaceuticals, Inc., GlaxoSmithKline, UCB, Sepracor Inc.,
Janssen Research Foundation, Eli Lilly and Company, National Alliance
for Research on Schizophrenia and Depression, and the National Institute
of Mental Health. She reports receiving consultant fees or honoraria
from Paramount BioSciences, Anxiety Disorders Association of America, American
Psychiatric Association, American Foundation for Suicide Prevention,
Forest Pharmaceuticals, Inc., Solvay, Sepracor Inc., UCB, and Pfizer.
For the period from November 2005 to June 2008, Dr. Campbell-Sills
reports no competing interests.
The Executive Committee on Practice Guidelines has reviewed
this guideline and found no evidence of influence from these relationships.
|